Institutional members access full text with Ovid®

Share this article on:

Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial

Haji Seyed Javadi, Alireza MD*; Shafikhani, Ali Akbar MSc; Zamir, Seyed Mohsen MD*; Khanshir, Zahra Farzane MD

Journal of Clinical Psychopharmacology: April 2018 - Volume 38 - Issue 2 - p 119–124
doi: 10.1097/JCP.0000000000000850
Original Contributions

Purpose/Background The effectiveness of selective-serotonin reuptake inhibitors in the improvement of schizophrenia is a controversial issue. The aim of this study was to evaluate the effect of fluvoxamine on the symptoms of schizophrenia including positive and negative symptoms, cognitive impairment, and quality of life.

Methods/Procedures This clinical trial was performed on 68 patients with chronic schizophrenia, treated with risperidone at 22 Bahman Hospital of Qazvin, Iran during 2015 to 2016. The patients were randomly divided into control and intervention groups (34 patients per group). The control group was treated with risperidone and biperiden, whereas the intervention group received fluvoxamine, besides risperidone, and biperiden. The participants completed the Wechsler Memory Scale, Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms (SANS), and the World Health Organization Quality of Life Scale, and the findings were statistically analyzed at baseline and postintervention (8 and 10 weeks).

Findings/Results The mean ± SD Wechsler Memory Scale scores in the evaluated intervals (baseline, week 8, and week 10), respectively, were 70.58 ± 11.51, 70.76 ± 11.36, and 70.88 ± 11.40 in the control group and 74.76 ± 10.56, 77.76 ± 10.56, and 77.76 ± 10.73 in the intervention group (F = 126.73, P ≤ 0.001). The difference between the groups in terms of SANS and quality of life scores was significant in the specified intervals, SANS (F = 6.36, P = 0.004), and quality of life (F = 15.13, P ≤ 0.001). Nevertheless, no difference was observed in terms of Scale for the Assessment of Positive Symptoms scores (P > 0.05).

Implications/Conclusions The results indicated that risperidone augmentation with fluvoxamine could significantly improve cognitive impairments and negative symptoms among patients with schizophrenia. Moreover, this augmentation led to higher quality of life among these patients.

From the *Department of Psychiatry, Faculty of Medicine, †Department of Occupational Health Engineering, Faculty of Health, and ‡Department of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

Received May 31, 2017; accepted after revision December 28, 2017.

Reprints: Alireza Haji Seyed Javadi, MD, Department of Psychiatry, 22 Bahman Hospital, Qazvin University of Medical Sciences, Qazvin, Iran (e-mail: ahsjavadi@qums.ac.ir).

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.